Skip to main content
SpringerLink
Log in

Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinson’s Disease

  • Review Article
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

When peripheral decarboxylation is blocked by carbidopa or benserazide, the main metabolic pathway of levodopa is O-methylation by catechol-O-methyltransferase (COMT). Entacapone and tolcapone are new potent, selective and reversible nitrocatechol-type COMT inhibitors. Animal studies have demonstrated that entacapone mainly has a peripheral effect whereas tolcapone also inhibits O-methylation in the brain. In human volunteers, both entacapone and tolcapone dose-dependently inhibit the COMT activity in erythrocytes, improve the bioavailability and decrease the elimination of levodopa, and inhibit the formation of 3-O-methyldopa (3-OMD). Entacapone is administered with every scheduled dose of levodopa whereas tolcapone is administered 3 times daily. The different administration regimens for these agents are based on their different pharmacokinetic and pharmacodynamic profiles.

Both entacapone and tolcapone enhance and extend the therapeutic effect of levodopa in patients with advanced and fluctuating Parkinson’s disease. They prolong the duration of levodopa effect. Clinical studies show that they increase the daily ON time by an average 1 to 3 hours, improve the activities of daily living and allow daily levodopa dosage to be decreased. Correspondingly, they significantly reduce the daily OFF time. No comparative studies between entacapone and tolcapone have been performed. Tolcapone also appears to have a beneficial effect in patients with nonfluctuating Parkinson’s disease.

The main adverse effects of the COMT inhibitors are related to their dopaminergic and gastrointestinal effects. Enhancement of dopaminergic activity may cause an initial worsening of levodopa-induced adverse effects, such as dyskinesia, nausea, vomiting, orthostatic hypotension, sleep disorders and hallucinations. Levodopa dose adjustment is recommended to avoid these events. Tolcapone is associated with diarrhoea in about 16 to 18% of patients and entacapone in less than 10% of patients. Diarrhoea has led to discontinuation in 5 to 6% of patients treated with tolcapone and in 2.5% of those treated with entacapone. Urine discoloration to dark yellow or orange is related to the colour of COMT inhibitors and their metabolites. Elevated liver transaminase levels are reported in 1 to 3% of patients treated with tolcapone but very rarely, if at all, in patients treated with entacapone. The descriptions of acute, fatal fulminant hepatitis and potentially fatal neurological reactions, such as neuroleptic malignant syndrome and rhabdomyolysis, in association with tolcapone led to the suspension of its marketing authorisation in the European Community and Canada. In many other countries, the use of tolcapone is restricted to patients who are not responding satisfactorily to other therapies. Regular monitoring of liver enzymes is required if tolcapone is used. No such adverse reactions have so far been described for entacapone and no laboratory monitoring has been proposed.

COMT inhibitors added to levodopa therapy are beneficial, particularly in patients with fluctuating disease. They may be combined with other antiparkinsonian drugs, such as dopamine agonists, selegiline and anticholinergics without adverse interactions. They provide a new treatment possibility in patients with Parkinson’s disease who have problems with their present levodopa therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Table I
Fig. 3
Table II
Fig. 4
Table III
Table IV
Table V
Table VI

Similar content being viewed by others

References

  1. Axelrod J. O-methylation of epinephrine and other catechols in vitro and in vivo. Science 1957; 126: 400–1

    Article  PubMed  CAS  Google Scholar 

  2. Guldberg HC, Marsden CA. Catechol-O-methyl transferase: pharmacological aspects and physiological role. Pharmacol Rev 1975; 27: 135–206

    PubMed  CAS  Google Scholar 

  3. Ericsson AD. Potentiation of the L-dopa effect in man by the use of catechol-O-methyltransferase inhibitors. J Neurol Sci 1971; 14: 193–7

    Article  PubMed  CAS  Google Scholar 

  4. Reches A, Fahn S. Catechol-O-methyltransferase and Parkinson’s disease. Adv Neurol 1984; 40: 171–9

    PubMed  CAS  Google Scholar 

  5. Männistö PT, Kaakkola S. Rationale for selective COMT inhibitors as adjuncts in the drug treatment of Parkinson’s disease. Pharmacol Toxicol 1990; 66: 317–23

    Article  PubMed  Google Scholar 

  6. Männistö PT, Ulmanen I, Taskinen J, et al. Catechol-O-methyltransferase (COMT) and COMT inhibitors. In: Sandier M, Smith J, editors. Design of enzyme inhibitors as drugs. Oxford: Oxford University Press, 1993; 623–46

    Google Scholar 

  7. Kaakkola S, Gordin A, Männistö PT. General properties and clinical possibilities of new selective inhibitors of catechol O-methyltransferase. Gen Pharmacol 1994; 25: 813–24

    Article  PubMed  CAS  Google Scholar 

  8. Pentikäinen PJ, Vuorela A, Järvinen M, et al. Human pharmacokinetics of OR-462, a new catechol-O-methyltransferase inhibitor. Eur J Clin Pharmacol 1989; 36 Suppl.: Al 10

    Google Scholar 

  9. Kaakkola S, Gordin A, Järvinen M, et al. Effect of a novel catechol-O-methyltransferase inhibitor, nitecapone, on the metabolism of L-dopa in healthy volunteers. Clin Neuropharmacol 1990; 13: 436–47

    Article  PubMed  CAS  Google Scholar 

  10. Bieck PR, Nilsson E, Antonin KH. Effect of the new selective COMT inhibitor CGP 28014 A on the formation of 3-O-methyldopa (3OMD) in plasma of healthy subjects. J Neural Transm Suppl 1990; 32: 387–91

    PubMed  CAS  Google Scholar 

  11. Bieck PR, Antonin KH, Farger G, et al. Clinical pharmacology of the new COMT inhibitor CGP 28, 014. Neurochem Res 1993; 18: 1163–7

    Article  PubMed  CAS  Google Scholar 

  12. Feuerstein C, Tanche M, Serre F, et al. Does O-methyl-dopa play a role in levodopa-induced dyskinesias? Acta Neurol Scand 1977; 56: 79–82

    Article  PubMed  CAS  Google Scholar 

  13. Rivera-Calimlim L, Tandon D, Anderson F, et al. The clinical picture and plasma levodopa metabolite profile of parkinsonian nonresponders. Treatment with levodopa and decarboxylase inhibitor. Arch Neurol 1977; 34: 228–32

    CAS  Google Scholar 

  14. Tohgi H, Abe T, Kikuchi T, et al. The significance of 3-O-methyldopa concentrations in the cerebrospinal fluid in the pathogenesis of wearing-off phenomenon in Parkinson’s disease. Neurosci Lett 1991; 132: 19–22

    Article  PubMed  CAS  Google Scholar 

  15. Wade LA, Katzman R. 3-O-Methyldopa uptake and inhibition of L-dopa at the blood-brain barrier. Life Sci 1975; 17: 131–6

    Article  PubMed  CAS  Google Scholar 

  16. McKenzie GM, White HL. Evidence for the methylation of apomorphine by catechol-O-methyl-transferase in vivo and in vitro. Biochem Pharmacol 1973; 22: 2329–36

    Article  PubMed  CAS  Google Scholar 

  17. Symes AL, Lal S, Sourkes TL. Effect of catechol-O-methyltransferase inhibitors on brain apomorphine concentrations and stereotyped behaviour in the rat. J Pharm Pharmacol 1975; 27: 947–9

    Article  PubMed  CAS  Google Scholar 

  18. Coudore F, Durif F, Duroux E, et al. Effect of tolcapone on plasma and striatal apomorphine disposition in rats. Neuroreport 1997; 8: 877–80

    Article  PubMed  CAS  Google Scholar 

  19. Kohli JD, Horn PT, Glock D, et al. Dihydrexidine: a new potent peripheral dopamine D1 receptor agonist. Eur J Pharmacol 1993; 235: 31–5

    Article  PubMed  CAS  Google Scholar 

  20. Keränen T, Gordin A, Karlsson M, et al. Inhibition of soluble catechol-O-methyltransferase and single-dose pharmacokinetics after oral and intravenous administration of entacapone. Eur J Clin Pharmacol 1994; 46: 151–7

    Article  PubMed  Google Scholar 

  21. Dingemanse J, Jorga KM, Schmitt M, et al. Integrated pharmacokinetics and pharmacodynamics of the novel catechol-O-methyltransferase inhibitor tolcapone during first administration to humans. Clin Pharmacol Ther 1995; 57: 508–17

    Article  PubMed  CAS  Google Scholar 

  22. Heikkinen H, Pentikäinen PJ, Saraheimo M, et al. Pharmacokinetics of entacapone, a new COMT-inhibitor, in man: a study using stable isotope technique. New Trends Clin Neuropharm 1994; 8: 301

    Google Scholar 

  23. Jorga KM, Fotteler B, Heizmann P, et al. Pharmacokinetics and pharmacodynamics after oral and intravenous administration of tolcapone, a novel adjunct to Parkinson’s disease therapy. Eur J Clin Pharmacol 1998; 54: 443–7

    Article  PubMed  CAS  Google Scholar 

  24. Wikberg T, Vuorela A, Ottoila P, et al. Identification of major metabolites of the catechol-O-methyltransferase inhibitor entacapone in rats and humans. Drug Metab Dispos 1993; 21: 81–92

    PubMed  CAS  Google Scholar 

  25. F. Hoffman-La Roche Ltd. Product monograph Tasmar. Basel: F. Hoffman-La Roche Ltd, 1997: 1–60

    Google Scholar 

  26. Da Prada M, Borgulya J, Napolitano A, et al. Improved therapy of Parkinson’s disease with tolcapone, a central and peripheral COMT inhibitor with an S-adenosyl-L-methionine-sparing effect. Clin Neuropharmacol 1995; 17: S26–S37

    Article  Google Scholar 

  27. Dingemanse J, Jorga K, Zürcher G, et al. Multiple-dose clinical pharmacology of the catechol-O-methyl-transferase inhibitor tolcapone in elderly subjects. Eur J Clin Pharmacol 1996; 50: 47–55

    Article  PubMed  CAS  Google Scholar 

  28. Jorga K, Fotteler B, Wiegand U. Tolcapone does not change the pharmacokinetics and pharmacodynamics of the CYP2C9 substrate tolbutamide. Mov Disord 1997; 12 Suppl. 1: 100

    Article  Google Scholar 

  29. Gordin A, Huupponen R, Rouru J, et al. Pharmacokinetics of entacapone and catechol-O-methyltransferase (COMT) inhibition after frequent multiple dosing of entacapone and effect on levodopa metabolism. Eur J Neurol 1998; 5 Suppl. 3: S165–S6

    Google Scholar 

  30. Jorga KM, Sedek G, Fotteler B, et al. Optimizing levodopa pharmacokinetics with multiple tolcapone doses in the elderly. Clin Pharmacol Ther 1997; 62: 300–10

    Article  PubMed  CAS  Google Scholar 

  31. Dingemanse J, Jorga K, Zürcher G, et al. Pharmacokinetic-pharmacodynamic interaction between the COMT inhibitor tolcapone and single-dose levodopa. Br J Clin Pharmacol 1995; 40: 253–62

    Article  PubMed  CAS  Google Scholar 

  32. Jorga K, Fotteler B, van Brummelen P. Why should tolcapone be given at a lower dose to patients with liver cirrhosis? Clin Pharmacol Ther 1997; 61: 183

    Google Scholar 

  33. Gordin A, Pentikäinen PP, Mäkimartti M, et al. Pharmacokinetics of the COMT inhibitor entacapone in liver failure and the effect of entacapone on liver function. Neurology 1998; 50 Suppl. 4: A387

    Google Scholar 

  34. Comtess Summary of Product Characteristics. Espoo, Finland: Orion Corp., 1998

  35. Schultz E, Nissinen E. Inhibition of rat liver and duodenum soluble catechol-O-methyltransferase by a tight-binding inhibitor OR-462. Biochem Pharmacol 1989; 38: 3953–6

    Article  PubMed  CAS  Google Scholar 

  36. Lotta T, Vidgren J, Tilgmann C, et al. Kinetics of human soluble and membrane-bound catechol O-methyltransferase: a revised mechanism and description of the thermolabile variant of the enzyme. Biochemistry 1995; 34: 4202–10

    Article  PubMed  CAS  Google Scholar 

  37. Borges N, Vieira-Coelho MA, Parada A, et al. Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain catechol-O-methyltransferase. J Pharmacol Exp Ther 1997; 282: 812–7

    PubMed  CAS  Google Scholar 

  38. Keränen T, Gordin A, Harjola VP, et al. The effect of catechol-O-methyl transferase inhibition by entacapone on the pharmacokinetics and metabolism of levodopa in healthy volunteers. Clin Neuropharmacol 1993; 16: 145–56

    Article  PubMed  Google Scholar 

  39. Sêdek G, Jorga K, Schmitt M, et al. Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers. Clin Neuropharmacol 1997; 20: 531–41

    Article  PubMed  Google Scholar 

  40. Jorga K, Fotteler B, Schmitt M, et al. The effect of COMT inhibition by tolcapone on tolerability and pharmacokinetics of different levodopa/benserazide formulations. Eur Neurol 1997; 38: 59–67

    Article  PubMed  CAS  Google Scholar 

  41. Myllylä VV, Sotaniemi KA, Mäkimartti M, et al. Effect of entacapone as an adjunct to Sinemet and Madopar on the pharmacokinetics of levodopa in parkinsonian patients. Mov Disord 1997; 12 Suppl. 1: 103

    Article  Google Scholar 

  42. Jorga K, Fotteler B, Sedek G, et al. The effect of tolcapone on levodopa pharmacokinetics is independent of levodopa/carbidopa formulation. J Neurol 1998; 245: 223–30

    Article  PubMed  CAS  Google Scholar 

  43. Ahtila S, Kaakkola S, Gordin A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopacarbidopa in volunteers. Clin Neuropharmacol 1995; 18: 46–57

    Article  PubMed  CAS  Google Scholar 

  44. Ruottinen HM, Rinne UK. A double-blind pharmacokinetic and clinical dose-response study of entacapone as an adjuvant to levodopa therapy in advanced Parkinson’s disease. Clin Neuropharmacol 1996; 19: 283–96

    Article  PubMed  CAS  Google Scholar 

  45. Ruottinen HM, Rinne UK. Effect of one month’s treatment with peripherally acting catechol-O-methyltransferase inhibitor, entacapone, on pharmacokinetics and motor response to levodopa in advanced parkinsonian patients. Clin Neuropharmacol 1996; 19: 222–33

    Article  PubMed  CAS  Google Scholar 

  46. Myllylä VV, Sotaniemi KA, Illi A, et al. Effect of entacapone, a COMT inhibitor, on the pharmacokinetics of levodopa and on cardiovascular responses in patients with Parkinson’s disease. Eur J Clin Pharmacol 1993; 45: 419–23

    Article  PubMed  Google Scholar 

  47. Nutt JG, Woodward WR, Beckner RM, et al. Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients. Neurology 1994; 44: 913–9

    Article  PubMed  CAS  Google Scholar 

  48. Tohgi H, Abe T, Yamazaki K, et al. Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson’s disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement. Neurosci Lett 1995; 192: 165–8

    Article  PubMed  CAS  Google Scholar 

  49. Roberts JW, Cora-Locatelli G, Bravi D, et al. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1993; 43: 2685–8

    Article  PubMed  CAS  Google Scholar 

  50. Limousin P, Pollak P, Pfefen JP, et al. Acute administration of levodopa-benserazide and tolcapone, a COMT inhibitor, Parkinson’s disease. Clin Neuropharmacol 1995; 18: 258–65

    Article  PubMed  CAS  Google Scholar 

  51. Yamamoto M, Yokochi M, Kuno S, et al. Effects of tolcapone, a catechol-O-methyltransferase inhibitor, on motor symptoms and pharmacokinetics of levodopa in patients with Parkinson’s disease. J Neural Transm 1997; 104: 229–36

    Article  PubMed  CAS  Google Scholar 

  52. Kaakkola S, Teräväinen H, Ahtila S, et al. Entacapone in combination with standard or controlled-release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson’s disease. Eur J Neurol 1995; 2: 341–7

    Article  Google Scholar 

  53. Kuruma I, Bartholini G, Tissot R, et al. The metabolism of L-3-O-methyldopa, a precursor of dopa in man. Clin Pharmacol Ther 1971; 12: 678–82

    PubMed  CAS  Google Scholar 

  54. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one month double blind study in parkinsonian patients with levodopa related fluctuations. J Neurol Neurosurg Psychiatry 1996; 60: 36–40

    Article  PubMed  CAS  Google Scholar 

  55. Sundberg S, Scheinin M, Illi A, et al. The effects of the COMT inhibitor entacapone on haemodynamics and peripheral catecholamine metabolism during exercise. Br J Clin Pharmacol 1993; 36: 451–6

    Article  PubMed  CAS  Google Scholar 

  56. Illi A, Sundberg S, Koulu M, et al. COMT inhibition by highdose entacapone does not affect hemodynamics but changes catecholamine metabolism in healthy volunteers at rest and during exercise. Int J Clin Pharmacol Ther 1994; 32: 582–8

    PubMed  CAS  Google Scholar 

  57. Zürcher G, Dingemanse J, Da Prada M. Potent COMT inhibition by Ro 40-7592 in the periphery and in the brain. Preclinical and clinical findings. Adv Neurol 1993; 60: 641–7

    Google Scholar 

  58. Lyytinen J, Kaakkola S, Ahtila S, et al. Simultaneous MAO-B and COMT inhibition in L-dopa-treated patients with Parkinson’s disease. Mov Disord 1997; 12: 497–505

    Article  PubMed  CAS  Google Scholar 

  59. Oechsner M, Stürenburg HJ, Buhmann C, et al. Elevated serum levels of dihydroxyphenylacetic acid (DOPAC) and dopamine after catechol-O-methyltransferase (COMT) inhibition. Eur J Neurol 1998; 5 Suppl. 3: S169

    Google Scholar 

  60. Davis TL, Roznoski M, Burns RS. Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline. Clin Neuropharmacol 1995; 18: 333–7

    Article  PubMed  CAS  Google Scholar 

  61. Tasmar Summary of Product Characteristics. Basle, Switzerland: F. Hoffman-La Roche Ltd., 1998

  62. Firnau G, Sood S, Chirakal R, et al. Metabolites of 6-[18F]fluoro-L-dopa in human blood. J Nucl Med 1988; 29: 363–9

    PubMed  CAS  Google Scholar 

  63. Firnau G, Sood S, Chirakal R, et al. Cerebral metabolism of 6-[18F]fluoro-L-3,4-dihydroxyphenylalanine in the primate. J Neurochem 1987; 48: 1077–82

    Article  PubMed  CAS  Google Scholar 

  64. Guttman M, Leger G, Cedarbaum JM. OR-611 inhibits 3-Omethyldopa formation in primates. Neurology 1991; 41: 213

    Google Scholar 

  65. Günther I, Psylla M, Reddy GN, et al. Positron emission tomography in drug evaluation: influence of three different catechol-O-methyltransferase inhibitors on metabolism of [NCA] 6-[18F]fluoro-L-dopa in rhesus monkey. Nucl Med Biol 1995; 22: 921–7

    Article  PubMed  Google Scholar 

  66. Doudet DJ, Chan GL, Holden JE, et al. Effects of catechol-O-methyltransferase inhibition on the rates of uptake and reversibility of 6-fluoro-L-dopa trapping in MPTP-induced parkinsonism in monkeys. Neuropharmacology 1997; 36: 363–71

    Article  PubMed  CAS  Google Scholar 

  67. Psylla M, Günther I, Antonini A, et al. Cerebral 6-[18F]fluoroL-DOPA uptake in rhesus monkey: pharmacological influence of aromatic amino acid decarboxylase (AAAD) and catechol-O-methyltransferase (COMT) inhibition. Brain Res 1997; 767: 45–54

    Article  PubMed  CAS  Google Scholar 

  68. Holden JE, Doudet D, Endres CJ, et al. Graphical analysis of 6-fluoro-L-dopa trapping: effect of inhibition of catechol-O-methyltransferase. J Nucl Med 1997; 38: 1568–74

    PubMed  CAS  Google Scholar 

  69. Laihinen A, Rinne JO, Rinne UK, et al. [18F]-6-fluorodopa PET scanning in Parkinson’s disease after selective COMT inhibition with nitecapone (OR-462). Neurology 1992; 42: 199–203

    Article  PubMed  CAS  Google Scholar 

  70. Sawle GV, Burn DJ, Morrish PK, et al. The effect of entacapone (OR-611) on brain [18F]-6-L-fluorodopa metabolism: implications for levodopa therapy of Parkinson’s disease. Neurology 1994; 44: 1292–7

    Article  PubMed  CAS  Google Scholar 

  71. Ishikawa T, Dhawan V, Chaly T, et al. Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis. J Cerebral Blood Flow Metab 1996; 16: 854–63

    Article  CAS  Google Scholar 

  72. Ruottinen H, Rinne J, Ruotsalainen U, et al. Striatal [18F]fluorodopa utilization after COMT inhibition with entacapone studied with PET in advanced Parkinson’s disease. J Neural Transm Park Dis Dem Sect 1995; 10: 91–106

    Article  CAS  Google Scholar 

  73. Ruottinen HM, Rinne JO, Oikonen VJ, et al. Striatal 6-[18F] fluorodopa accumulation after combined inhibition of peripheral catechol-O-methyltransferase and monoamine oxidase type B: differing response in relation to presynaptic dopaminergic dysfunction. Synapse 1997; 27: 336–46

    Article  PubMed  CAS  Google Scholar 

  74. Merello M, Lees AJ, Webster R, et al. Effect of entacapone, a peripherally acting catechol-O-methyltransferase inhibitor, on the motor response to acute treatment with levodopa in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry 1994; 57: 186–9

    Article  PubMed  CAS  Google Scholar 

  75. Davis TL, Roznoski M, Burns RS. Effects of tolcapone in Parkinson’s patients taking L-dihydroxyphenylalanine/carbidopa and selegiline. Mov Disord 1995; 10: 349–51

    Article  PubMed  CAS  Google Scholar 

  76. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Ann Neurol 1997; 42: 747–55

    Article  Google Scholar 

  77. Rinne UK, Larsen JP, Siden Å, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Neurology 1998; 51: 1309–14

    Article  PubMed  CAS  Google Scholar 

  78. Adler CH, Singer C, O’Brien C, et al. Randomized, placebocontrolled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Arch Neurol 1998; 55: 1089–95

    Article  PubMed  CAS  Google Scholar 

  79. Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson’s disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 1997; 48: 81–7

    CAS  Google Scholar 

  80. Myllylä W, Jackson M, Larsen JP, et al. Efficacy and safety of tolcapone in levodopa-treated Parkinson’s disease patients with ‘wearing-off’ phenomenon: a multicentre, double-blind, randomized, placebo-controlled study. Eur J Neurol 1997; 4: 333–41

    Article  Google Scholar 

  81. Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyl-transferase inhibition with tolcapone reduces the ‘wearing off’ phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry 1997; 63: 421–8

    Article  PubMed  CAS  Google Scholar 

  82. Rajput AH, Martin W, Sainthilaire MH, et al. Tolcapone improves motor function in parkinsonian patients with the ‘wearing-off’ phenomenon: a double-blind, placebo-controlled, multicenter trial. Neurology 1997; 49: 1066–71

    Article  PubMed  CAS  Google Scholar 

  83. Limousin P, Pollak P, Gervason-Tournier CL, et al. Ro 40-7592, a COMT inhibitor, plus levodopa in Parkinson’s disease. Lancet 1993; 341: 1605

    Article  PubMed  CAS  Google Scholar 

  84. Roberts JW, Cora-Locatelli G, Bravi D, et al. Catechol-O-methyltransferase (COMT) inhibitor Ro 40-7592 prolongs duration of action of levodopa/carbidopa in parkinsonian patients. Neurology 1993; 43 Suppl. 2: A332

    Article  Google Scholar 

  85. Dupont E, Burgunder JM, Findley LJ, et al. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Mov Disord 1997; 12: 928–34

    Article  PubMed  CAS  Google Scholar 

  86. Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson’s disease: efficacy and safety of long-term treatment. Neurology 1997; 49: 665–71

    Article  PubMed  CAS  Google Scholar 

  87. Agid Y, Destee A, Durif F, et al. Tolcapone, bromocriptine, and Parkinson’s disease. Lancet 1997; 350: 712–3

    Article  PubMed  CAS  Google Scholar 

  88. Harper J, Vieira B. Catechol-O-methyltransferase inhibitors in Parkinson’s disease. Lancet 1998; 352: 578

    Article  PubMed  CAS  Google Scholar 

  89. Henry C, Wilson JA. Catechol-O-methyltransferase inhibitors in Parkinson’s disease. Lancet 1998; 351: 1965–6

    Article  PubMed  CAS  Google Scholar 

  90. Hauser RA, Molho E, Shale H, et al. A pilot evaluation of the tolerability, safety, and efficacy of tolcapone alone and in combination with oral selegiline in untreated Parkinson’s disease patients. Mov Disord 1998; 13: 643–7

    Article  PubMed  CAS  Google Scholar 

  91. Assal F, Spahr L, Hadengue A, et al. Tolcapone and fulminant hepatitis. Lancet 1998; 352: 958

    Article  PubMed  CAS  Google Scholar 

  92. EMEA. Recommendation for the suspension of the marketing authorisation for Tasmar (tolcapone) [press release]. Vol. CPMP/2457/98. London, 1998

  93. Tasmar Product Label. Nutley (NJ): Roche Laboratories Inc., 1998

  94. Jorga KM, Larsen JP, Beiske A, et al. The effect of tolcapone on the pharmacokinetics of benserazide. Eur J Neurol 1999; 6: 211–19

    Article  PubMed  CAS  Google Scholar 

  95. Tedroff J, Hartvig P, Bjurling P, et al. Central action of benserazide after COMT inhibition demonstrated in vivo by PET. J Neural Transm Gen Sect 1991; 85: 11–7

    Article  PubMed  CAS  Google Scholar 

  96. Illi A, Sundberg S, Ojala-Karlsson P, et al. The effect of entacapone on the disposition and hemodynamic effects of intravenous isoproterenol and epinephrine. Clin Pharmacol Ther 1995; 58: 221–7

    Article  PubMed  CAS  Google Scholar 

  97. Lyytinen J, Kaakkola S, Teräväinen H, et al. Comparison between the effects of L-dopa + entacapone and L-dopa + placebo on exercise capacity, haemodynamics and autonomic function in patients with Parkinson’s disease. Mov Disord 1997; 12 Suppl. 1: 103

    Article  Google Scholar 

  98. Sedek G, Jorga K, Yoo K, et al. Lack of interaction between ephedrine and combination of tolcapone and sinemet. eurology 1996; 46 Suppl. 2: 374

    Google Scholar 

  99. Illi A, Sundberg S, Ojala-Karlsson P, et al. Simultaneous inhibition of catechol-O-methyltransferase and monoamine oxidase A: effects on hemodynamics and catecholamine metabolism in healthy volunteers. Clin Pharmacol Ther 1996; 59: 450–7

    Article  PubMed  CAS  Google Scholar 

  100. Illi A, Sundberg S, Ojala-Karlsson P, et al. Simultaneous inhibition of catecholamine-O-methylation by entacapone and neuronal uptake by imipramine: lack of interactions. Eur J Clin Pharmacol 1996; 51: 273–6

    Article  PubMed  CAS  Google Scholar 

  101. Jorga K, Fotteler B, Sedek G, et al. Effect of the COMT inhibitor tolcapone on the hemodynamics effects and tolerability of the combination treatment with levodopa/carbidopa and desipramine in healthy volunteers. Neurology 1997; 48 Suppl.: A185

    Google Scholar 

  102. Campbell NRC, Hasinoff BB. Iron supplements: a common cause of drug interactions. Br J Clin Pharmacol 1991; 31: 251–5

    Article  PubMed  CAS  Google Scholar 

  103. Orama M, Tilus P, Taskinen J, et al. Iron(III)-chelating properties of the novel catechol O-methyltransferase inhibitor entacapone in aqueous solution. J Pharm Sci 1997; 86: 827–31

    Article  PubMed  CAS  Google Scholar 

  104. Nutt JG. Catechol-O-methyltransferase inhibitors for treatment of Parkinson’s disease. Lancet 1998; 351: 1221–2

    Article  PubMed  CAS  Google Scholar 

  105. Khromova I, Voronina T, Kraineva VA, et al. Effects of selective catechol-O-methyltransferase inhibitors on single-trial passive avoidance retention in male rats. Behav Brain Res 1997; 86: 49–57

    Article  PubMed  CAS  Google Scholar 

  106. Moreau JL, Borgulya J, Jenck F, et al. Tolcapone: a potential new antidepressant detected in a novel animal model of depression. Behav Pharmacol 1994; 5: 344–50

    Article  PubMed  CAS  Google Scholar 

  107. Da Prada M, Borgulya J, Napolitano A, et al. Improved therapy of Parkinson’s Disease with tolcapone, a central and peripheral COMT inhibitor with an S-adenosyl-L-methione-sparing effect. Clin Neuropharmacol 1994; 17 Suppl. 3: S26–37

    Article  Google Scholar 

  108. Yassin MS, Cheng H, Ekblom J, et al. Inhibitors of catecholamine metabolizing enzymes cause changes in S-adenosylmethionine and S-adenosylhomocysteine in the rat brain. Neurochem Int 1998; 32: 53–9

    Article  PubMed  CAS  Google Scholar 

  109. Gasparini M, Fabrizio E, Bonifati V, et al. Cognitive improvement during tolcapone treatment in Parkinson’s disease. J Neural Transm 1997; 104: 887–94

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, University of Helsinki, Haartmaninkatu 4, 00290, Helsinki, Finland

    Seppo Kaakkola

Authors
  1. Seppo Kaakkola
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kaakkola, S. Clinical Pharmacology, Therapeutic Use and Potential of COMT Inhibitors in Parkinson’s Disease. Drugs 59, 1233–1250 (2000). https://doi.org/10.2165/00003495-200059060-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003495-200059060-00004

Keywords

Search

Navigation